重组人脑利钠肽在急性心肌梗死后心力衰竭治疗中的应用及其对循环内分泌的影响

Application of recombinant human brain natriuretic peptide in the treatment of heart failure after acute myocardial infarction and its effect on circulatory endocrine

目的探讨重组人脑利钠肽在急性心肌梗死后心力衰竭治疗中的应用及其对循环内分泌的影响。方法选择2018年9月至2019年3月收治的112例急性心肌梗死后心力衰竭患者作为研究对象,根据随机数字表法分为对照组和观察组,各56例。对照组给予基础治疗,观察组采用重组人脑利钠肽治疗,1个月后对患者效果进行评估,比较两组患者ALD、PRA、ATⅡ、心率、收缩压、中心静脉压。结果经1个月治疗后两组患者ALD、PRA、ATⅡ显著降低,观察组ALD、PRA、ATⅡ均显著低于对照组(P<0.05)。观察组患者的心率、收缩压、中心静脉压均优于对照组(P<0.05)。结论将重组人脑利钠肽用于急性心肌梗死后心力衰竭治疗中对于循环内分泌系统功能异常具有十分显著的抑制作用,值得推广应用。

Objective To investigate the application of recombinant human brain natriuretic peptide(rhBNP)in the treatment of heart failure after acute myocardial infarction(AMI)and its effect on circulatory endocrine.Methods 112 patients with heart failure after acute myocardial infarction treated from September 2018 to March 2019 were selected as subjects.The patients were randomly divided into control group and observation group,with 56 cases in each group.The control group was given basic treatment,while the observation group was treated with recombinant human brain natriuretic peptide.One month later,the effect of the patients was evaluated.ALD,PRA,ATⅡ,heart rate,systolic blood pressure and central venous pressure were compared between the two groups.Results After one month treatment,ALD,PRA and ATⅡ in the two groups were significantly decreased,and ALD,PRAandATⅡ in the observation group were significantly lower than those in the control group(P<0.05).The heart rate,systolic blood pressure and central venous pressure in the observation group were better than those in the control group(P<0.05).Conclusion Recombinant human brain natriuretic peptide(rhBNP)can significantly inhibit the dysfunction of circulatory endocrine system in the treatment of heart failure after acute myocardial infarction,which is worthy of popularization and application.